Dr. Jing Qin 覃晶
Chief Physician
Department of Medical Oncology for Thoracic Tumors, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Medical treatment of thoracic tumors, including lung cancer, esophageal cancer, and mediastinal tumors.
Dr. Jing Qin is a Chief Physician with a medical doctorate at Zhejiang Cancer Hospital. The physician focuses on comprehensive treatment of malignant tumors, primarily chemotherapy and targeted therapy. Dr. Qin participated in three National and Provincial Natural Science Foundation projects and led one Health Department project. Ten academic papers were published, including three indexed by SCI, and one specialist book was co-edited.
Professional roles
- Member, Tumor Immunology and Biotherapy Professional Committee, Zhejiang Immunological Society
Name order: in Chinese the family name comes first (Qin Jing). Papers usually list the name as Jing Qin or Qin J.
Selected publications
44 papers on PubMed matched by name and affiliation; 12 as first or senior author since 2016. Most recent first- or senior-author papers:
- Phytother Res, 2026 (first author): Curcumol Inhibits the Laminin-Facilitated Malignant Progression in Small-Cell Lung Cancer via Disrupting Laminin-Integrin β1 Interaction. PubMed 42374834
- Adv Healthc Mater, 2026 (senior author): A Novel Metal-Phenolic-Protein Hybrid Nanoparticles With Precise Delivery and Enhanced Penetration Effect for tPA Targeted Thrombolysis and Reduced Hemorrhagic Risk. PubMed 41367074
- Transl Lung Cancer Res, 2024 (senior author): Tumor mutation burden and FAT3 mutation influence long-term survival in surgically resected small cell lung cancer. PubMed 38973948
- J Cancer Res Clin Oncol, 2024 (senior author): Predictive biomarkers for immunotherapy response in extensive-stage SCLC. PubMed 38245636
- Chem Biol Interact, 2023 (senior author): Shikonin suppresses small cell lung cancer growth via inducing ATF3-mediated ferroptosis to promote ROS accumulation. PubMed 37268198
- Discov Oncol, 2023 (senior author): Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report. PubMed 37055606
- Pathol Oncol Res, 2021 (first author): MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma. PubMed 34257619
- Cancer Genet, 2021 (first author): Genetic heterogeneity and predictive biomarker for pulmonary sarcomatoid carcinomas. PubMed 33217678
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion